What is Gyre Therapeutics, Inc.'s free cash flow margin?

Gyre Therapeutics, Inc. (GYRE) reported free cash flow margin of 2.6% in Q1 2026.

What does free cash flow margin mean?

Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.

Gyre Therapeutics, Inc. GYRE Free cash flow margin

Free cash flow margin at other companies

Eli LillyLLY

16.4%+8.7pp

Madrigal Pharmaceuticals, Inc.MDGL

-59.8%-29.6pp

Theravance BiopharmaTBPH

221.9%+206pp

Zevra Therapeutics, Inc.ZVRA

-75%-30.5pp

LQD

Liquidia CorporationLQDA

-150.7%-64.4pp

BridgeBio PharmaBBIO

-76.8%—

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

free cash flow/total revenue=2.6%

Based on trailing twelve months.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s free cash flow margin?: Gyre Therapeutics, Inc. (GYRE) reported free cash flow margin of 2.6% in Q1 2026.
What does free cash flow margin mean?: Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.